JP2022520596A5 - - Google Patents
Info
- Publication number
- JP2022520596A5 JP2022520596A5 JP2021547322A JP2021547322A JP2022520596A5 JP 2022520596 A5 JP2022520596 A5 JP 2022520596A5 JP 2021547322 A JP2021547322 A JP 2021547322A JP 2021547322 A JP2021547322 A JP 2021547322A JP 2022520596 A5 JP2022520596 A5 JP 2022520596A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- therapy
- treatment
- composition according
- deprivation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805291P | 2019-02-13 | 2019-02-13 | |
| US62/805,291 | 2019-02-13 | ||
| PCT/US2020/018160 WO2020168110A1 (en) | 2019-02-13 | 2020-02-13 | Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520596A JP2022520596A (ja) | 2022-03-31 |
| JP2022520596A5 true JP2022520596A5 (enExample) | 2023-02-21 |
Family
ID=72045655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547322A Pending JP2022520596A (ja) | 2019-02-13 | 2020-02-13 | 前立腺がんを治療するための新規マーカーとしてのｅｐｈｂ４－エフリンｂ２受容体リガンド対 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220153791A1 (enExample) |
| EP (1) | EP3923969A4 (enExample) |
| JP (1) | JP2022520596A (enExample) |
| KR (1) | KR20220010469A (enExample) |
| CN (1) | CN114007633A (enExample) |
| AU (1) | AU2020221276A1 (enExample) |
| CA (1) | CA3139416A1 (enExample) |
| WO (1) | WO2020168110A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| AU2020241963B2 (en) * | 2019-03-17 | 2026-07-02 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
| CN117120074A (zh) * | 2021-03-18 | 2023-11-24 | V·卡拉斯诺佩洛夫 | sEphB4-HSA融合蛋白作为癌症治疗的一线疗法的用途 |
| CN118290563B (zh) * | 2024-06-03 | 2024-08-02 | 磐如生物科技(天津)有限公司 | 一种前列腺癌抗原肽和免疫佐剂组合物及其在抗肿瘤中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| AU2005277641A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| WO2006034455A2 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Polipeptide compounds for inhibiting angiogenesis and tumor growth |
| WO2012068477A1 (en) * | 2010-11-19 | 2012-05-24 | Vasgene Therapeutics, Inc. | Methods and compositions for inhibiting angiogenesis and tumor growth |
| CA2892490A1 (en) * | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| AU2020241963B2 (en) * | 2019-03-17 | 2026-07-02 | Vasgene Therapeutics Inc | Treatment of cancers using sEphB4-HSA fusion proteins |
-
2020
- 2020-02-13 CA CA3139416A patent/CA3139416A1/en active Pending
- 2020-02-13 WO PCT/US2020/018160 patent/WO2020168110A1/en not_active Ceased
- 2020-02-13 KR KR1020217029023A patent/KR20220010469A/ko not_active Ceased
- 2020-02-13 JP JP2021547322A patent/JP2022520596A/ja active Pending
- 2020-02-13 AU AU2020221276A patent/AU2020221276A1/en not_active Abandoned
- 2020-02-13 US US17/430,186 patent/US20220153791A1/en not_active Abandoned
- 2020-02-13 EP EP20756368.5A patent/EP3923969A4/en not_active Withdrawn
- 2020-02-13 CN CN202080028627.1A patent/CN114007633A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3443119B2 (ja) | 腫瘍壊死因子結合リガンド | |
| JP4202417B2 (ja) | Ｉｌ−１３受容体特異的キメラタンパク質およびその用途 | |
| EP2760886B1 (en) | Immunocytokine combination therapy | |
| JP7169298B2 (ja) | ヒトアルファフェトタンパク質特異的ｔ細胞受容体およびその使用 | |
| CZ330694A3 (en) | Immuno-conjugates | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| WO1985000974A1 (en) | Antibody compositions of therapeutic agents having an extended serum half-life | |
| JP2020105219A (ja) | 癌治療のための改善された細胞組成物および方法 | |
| JP2016505807A (ja) | Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング | |
| AU2019389807B2 (en) | Combined treatment of primary central nervous system lymphoma | |
| CA2723823C (en) | Conjugates for the treatment of mesothelioma | |
| CN115666645A (zh) | 用于脑瘤治疗的TNFα免疫缀合物疗法 | |
| KR20250092133A (ko) | 면역억제성 종양미세환경을 조절하는 항체-펩타이드 융합체 및 이의 항암용도 | |
| CN115304680B (zh) | 基于Pep42构建的双特异性细胞接合器分子的制备及其应用 | |
| JP2024534935A5 (enExample) | ||
| Semprini et al. | HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody | |
| JP2024511995A5 (enExample) | ||
| JP2024527963A5 (enExample) | ||
| CN120441708A (zh) | 一种靶向cd3和l1cam的双特异性抗体及其应用 | |
| EP0467416A1 (en) | Antibody compositions of therapeutic agents having an extended serum half-life | |
| WO2025021073A9 (zh) | 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途 | |
| EP4210752A1 (en) | Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers | |
| JP2022131943A (ja) | ワクチン、医薬及び糖尿病合併症治療薬 | |
| Kawakami | Cytokine Receptor as the Target for Immunotherapy | |
| Dillman | Biological therapy of breast cancer |